UBS has initiated coverage for Salix Pharmaceuticals (NASDAQ: SLXP) at Neutral with a $45 price target.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: salix UBSInitiation Analyst Ratings
| Stock | Firm | Action | PT |
|---|---|---|---|
| SEDG | B of A Securities | Maintains | 411.0 |
| PTLO | Piper Sandler | Maintains | 28.0 |
| AOUT | Lake Street | Maintains | 26.0 |
| RAPT | Piper Sandler | Maintains | 52.0 |
| OCX | Lake Street | Maintains | 6.0 |
Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com
